RxDoctor Payments Data

Esther Browne-King, MD

Internal Medicine · Temple Terrace, FLNPI 1780792853

Payments from drug & device makers

$544in general payments, 2019–2025

Across 29 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$143
  • GSK$63
  • Pfizer$55
  • Exact Sciences$53
  • Amgen$46
  • Astellas Pharma US Inc$33
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$544100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$544 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$14,566
Medicare patients
54
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin120$108,145
OzempicSemaglutide63$95,226
EliquisApixaban105$73,454
RybelsusSemaglutide23$36,025
TrulicityDulaglutide22$32,314
Spiriva HandihalerTiotropium Bromide45$27,341
MounjaroTirzepatide18$24,843
MyrbetriqMirabegron27$19,583
SymbicortBudesonide/Formoterol Fumarate73$19,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,657
Celecoxib99$10,625
JanuviaSitagliptin Phosphate13$10,336
TradjentaLinagliptin13$6,420
Albuterol Sulfate HfaAlbuterol Sulfate224$4,964
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$4,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$30$131,25186 claims
Boehringer IngelheimJardiance, Tradjenta$14$114,565133 claims
PfizerEliquis$55$73,454105 claims
Lilly USA, LLCTrulicity, Mounjaro$143$57,15740 claims
Astellas Pharma US IncMyrbetriq$33$19,58327 claims
AstraZenecaSymbicort$28$19,24473 claims
GSKTrelegy Ellipta$63$15,65723 claims
Sanofi-aventis U.S. LLCLantus$13$2,02214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Temple Terrace

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →